Citadel Advisors’s Apogee Therapeutics APGE Stock Holding History

Citadel Advisors’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$929K	Sell	7,000 -26,700	-79%	-$2.41M	﹤0.01%	8379
2026 Q1	$2.84M	Buy	33,700 +19,500	+137%	+$1.42M	﹤0.01%	5386
2025 Q4	$1.07M	Sell	14,200 -6,300	-31%	-$397K	﹤0.01%	7240
2025 Q3	$814K	Buy	20,500 +8,900	+77%	+$340K	﹤0.01%	7990
2025 Q2	$504K	Buy	11,600 +3,800	+49%	+$145K	﹤0.01%	8610
2025 Q1	$291K	Buy	7,800 +4,700	+152%	+$182K	﹤0.01%	9668
2024 Q4	$140K	Sell	3,100 -5,200	-63%	-$265K	﹤0.01%	10990
2024 Q3	$488K	Buy	8,300 +6,100	+277%	+$292K	﹤0.01%	8309
2024 Q2	$86.6K	Buy	2,200 +2,000	+1,000%	+$97.1K	﹤0.01%	11115
2024 Q1	$13.3K	Buy	+200	New	+$8.73K	﹤0.01%	13308

Other funds holding APGE

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Citadel Advisors's APGE Position: Q2 2026 in Review

Citadel Advisors reduced its Apogee Therapeutics (APGE) stake by 93% in Q2 2026, selling an estimated $50M and leaving 43,857 shares worth $5.82M. The position accounts for ﹤0.01% of the portfolio, ranked #4469.

Citadel Advisors first reported a position in APGE in Q3 2023 and has held it in 9 quarters since. The position peaked at $57.9M in Q4 2025. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

Citadel Advisors held 43,857 shares of Apogee Therapeutics worth $5.82M as of Q2 2026.
Citadel Advisors sold 555,045 Apogee Therapeutics shares in Q2 2026, an estimated $50M.
Apogee Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #4469 holding.
Citadel Advisors first reported a position in Apogee Therapeutics in Q3 2023 and has held it in 9 quarters since.
Citadel Advisors's Apogee Therapeutics position peaked at $57.9M in Q4 2025.
289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.